Regeneron Pharmaceuticals has announced plans to acquire the genetic testing company 23andMe for $256 million, with a clear ...

Some public libraries have yearbooks from the schools that used to serve their towns. The Hoyt Memorial Library in Kingston ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

Republican senators John Cornyn and Chuck Grassley and Democratic Sen. Amy Klobuchar are rolling out a bipartisan measure to protect sensitive genetic data in response to privacy concerns sparked by ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?